AU742970C - Method of suppressing beta-amyloid-related changes in Alzheimer's disease - Google Patents

Method of suppressing beta-amyloid-related changes in Alzheimer's disease

Info

Publication number
AU742970C
AU742970C AU17099/99A AU1709999A AU742970C AU 742970 C AU742970 C AU 742970C AU 17099/99 A AU17099/99 A AU 17099/99A AU 1709999 A AU1709999 A AU 1709999A AU 742970 C AU742970 C AU 742970C
Authority
AU
Australia
Prior art keywords
disease
amyloid
mammal
administration
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU17099/99A
Other languages
English (en)
Other versions
AU1709999A (en
AU742970B2 (en
Inventor
Dennis J. Selkoe
Howard L. Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland ULC
Original Assignee
Neuralab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26747618&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU742970(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuralab Ltd filed Critical Neuralab Ltd
Publication of AU1709999A publication Critical patent/AU1709999A/en
Application granted granted Critical
Publication of AU742970B2 publication Critical patent/AU742970B2/en
Priority to AU27727/02A priority Critical patent/AU781126B2/en
Assigned to NEURALAB LIMITED reassignment NEURALAB LIMITED Alteration of Name(s) in Register under S187 Assignors: BRIGHAM AND WOMEN'S HOSPITAL
Publication of AU742970C publication Critical patent/AU742970C/en
Assigned to ELAN PHARMA INTERNATIONAL LIMITED reassignment ELAN PHARMA INTERNATIONAL LIMITED Alteration of Name(s) in Register under S187 Assignors: NEURALAB LIMITED
Assigned to JANSSEN ALZHEIMER IMMUNOTHERAPY reassignment JANSSEN ALZHEIMER IMMUNOTHERAPY Alteration of Name(s) in Register under S187 Assignors: ELAN PHARMA INTERNATIONAL LIMITED
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Engine Equipment That Uses Special Cycles (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU17099/99A 1997-12-03 1998-12-03 Method of suppressing beta-amyloid-related changes in Alzheimer's disease Expired AU742970C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU27727/02A AU781126B2 (en) 1997-12-03 2002-03-28 Method of suppressing beta-amyloid-related changes in Alzheimer's disease

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6721997P 1997-12-03 1997-12-03
US60/067219 1997-12-03
US7969798P 1998-03-27 1998-03-27
US60/079697 1998-03-27
PCT/US1998/025694 WO1999027949A1 (en) 1997-12-03 1998-12-03 METHOD OF SUPPRESSING β-AMYLOID-RELATED CHANGES IN ALZHEIMER'S DISEASE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU27727/02A Division AU781126B2 (en) 1997-12-03 2002-03-28 Method of suppressing beta-amyloid-related changes in Alzheimer's disease

Publications (3)

Publication Number Publication Date
AU1709999A AU1709999A (en) 1999-06-16
AU742970B2 AU742970B2 (en) 2002-01-17
AU742970C true AU742970C (en) 2003-03-20

Family

ID=26747618

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17099/99A Expired AU742970C (en) 1997-12-03 1998-12-03 Method of suppressing beta-amyloid-related changes in Alzheimer's disease

Country Status (8)

Country Link
EP (1) EP1033998B1 (https=)
JP (2) JP2002511385A (https=)
AT (1) ATE306931T1 (https=)
AU (1) AU742970C (https=)
CA (1) CA2312475C (https=)
DE (2) DE69831971T2 (https=)
ES (1) ES2253839T3 (https=)
WO (1) WO1999027949A1 (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997021728A1 (en) 1995-12-12 1997-06-19 Karolinska Innovations Ab PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
EP1033998B1 (en) * 1997-12-03 2005-10-19 Neuralab, Ltd. Suppressing beta-amyloid-related changes in alzheimer's disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US7060670B1 (en) 1999-05-05 2006-06-13 Neurochem (International) Limited Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US6713450B2 (en) 2000-05-22 2004-03-30 New York University Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid β for induction of an immune response to amyloid β and amyloid deposits
EP1309341A2 (en) 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US7479482B2 (en) 2001-11-21 2009-01-20 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid β, prion protein, amylin, α-synuclein, or polyglutamine repeats for induction of an immune response thereto
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
SI1524994T1 (sl) 2002-07-19 2011-08-31 Cytos Biotechnology Ag Sestavki cepiv, ki vsebujejo amiloidne beta 1-6 antigenske mreĹľe
WO2004056318A2 (en) 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
TW200636066A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized antibodies that recognize beta amyloid peptide
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
WO2013012811A2 (en) 2011-07-19 2013-01-24 New York University Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
WO2013013056A1 (en) 2011-07-19 2013-01-24 New York University Method for treating amyloid disease
US20150290158A1 (en) * 2012-11-09 2015-10-15 Elliott C. Lasser X-ray contrast media compositions and methods of using the same to treat, reduce or delay the onset of cns inflammation and inflammation associated conditions
EP3166970B1 (en) 2014-07-10 2021-03-10 BioArctic AB Improved a-beta protofibril binding antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223482A (en) * 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
ATE153534T1 (de) * 1990-04-27 1997-06-15 John Mcmichael Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein
AU686818B2 (en) * 1994-05-25 1998-02-12 John Mcmichael Materials and methods for treatment of plaquing diseases
WO1996039176A1 (en) * 1995-06-05 1996-12-12 Brigham & Women's Hospital USE OF ORAL TOLERANCE TO SUPPRESS BOTH Th1 AND Th2 IMMUNE RESPONSES AND TO SUPPRESS ANTIBODY PRODUCTION
WO1997018855A1 (en) * 1995-11-21 1997-05-29 Eduard Naumovich Lerner Device for enhanced delivery of biologically active substances and compounds in an organism
ZA97452B (en) * 1996-01-25 1997-08-15 Trinity College Dublin Streptococcus equi vaccine.
JPH09208485A (ja) * 1996-01-31 1997-08-12 Teijin Ltd ペプチド・蛋白質性薬物の水難溶性組成物
EP1033998B1 (en) * 1997-12-03 2005-10-19 Neuralab, Ltd. Suppressing beta-amyloid-related changes in alzheimer's disease

Also Published As

Publication number Publication date
AU1709999A (en) 1999-06-16
JP2002511385A (ja) 2002-04-16
CA2312475C (en) 2010-08-03
ES2253839T3 (es) 2006-06-01
EP1033998B1 (en) 2005-10-19
DE69831971T2 (de) 2006-07-06
EP1033998A1 (en) 2000-09-13
DE1033998T1 (de) 2001-05-23
JP2010215627A (ja) 2010-09-30
AU742970B2 (en) 2002-01-17
ATE306931T1 (de) 2005-11-15
WO1999027949A1 (en) 1999-06-10
WO1999027949A9 (en) 1999-09-10
CA2312475A1 (en) 1999-06-10
DE69831971D1 (de) 2006-03-02
EP1033998A4 (en) 2003-06-04

Similar Documents

Publication Publication Date Title
AU742970C (en) Method of suppressing beta-amyloid-related changes in Alzheimer's disease
JP3712260B2 (ja) 自己免疫疾患のバイスタンダー抑制
US5763396A (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
JP4216342B2 (ja) コポリマー１の摂取又は吸入を通じての多発性硬化症の治療
US5720955A (en) Method of treating rheumatoid arthritis with soluble collagen
WO1994007520A1 (en) Method of treating rheumatoid arthritis with type ii collagen
HUP0001960A2 (hu) Metotrexát kombináció autoimmun tünetek befolyásolására
US20010007758A1 (en) Treatment of multiple sclerosis using COP-1 and Th2-enhancing cytokines
KR0159046B1 (ko) 포유류의 자기면역 포도막망막염의 치료 또는 예방방법
JPH09511990A (ja) 経口寛容および／またはＴｈ２増強サイトカインを用いた自己免疫疾患の治療
US6812205B2 (en) Suppression of vascular disorders by mucosal administration of heat shock protein peptides
AU781126B2 (en) Method of suppressing beta-amyloid-related changes in Alzheimer's disease
CA2410563C (en) Methods for preventing strokes by inducing tolerance to e-selectin
AU2001264813A1 (en) Methods for preventing strokes by inducing tolerance to E-selectin
WO2007028133A2 (en) Treatment and prevention of vascular dementia
EP0662838A1 (en) Method of treating rheumatoid arthritis with type ii collagen

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NEURALAB LIMITED

Free format text: FORMER OWNER WAS: BRIGHAM AND WOMEN'S HOSPITAL

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE PROPOSED AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20020702

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS WAS NOTIFIED IN THE OFFICIAL JOURNAL DATED 20020912

MK14 Patent ceased section 143(a) (annual fees not paid) or expired